Haemonetics Corporation

Haemonetics Corporation is a publicly-traded global medical technology company founded in 1971. Headquartered in Boston, Massachusetts, the company trades on the New York Stock Exchange under the ticker HAE. For its 2026 fiscal year, Haemonetics reported revenue of approximately $1.33 billion and has a market capitalization of around $2.5 billion. The company employs over 3,000 people.

Haemonetics develops and manufactures a range of products for blood and plasma collection and processing, as well as for use in surgical settings. Its business is organized into three main segments: Plasma, Blood Center, and Hospital. The Plasma segment provides automated plasma collection systems, disposables, and software. The Blood Center division offers automated blood component collection technology. The Hospital segment includes interventional technologies like vascular closure devices and blood management technologies such as cell salvage (autotransfusion) systems and hemostasis management diagnostics.

As a litigant, Haemonetics is primarily an operating company asserting its patents against competitors. The provided data shows the company as a plaintiff in five of six tracked cases, indicating an active strategy of patent enforcement rather than defense against non-practicing entities (NPEs). The jurisdictions of its recent cases include federal district courts in Colorado and Illinois, as well as the USPTO Patent Trial and Appeal Board (PTAB).

The tracked cases highlight disputes with major competitors in the blood and plasma technology sector. Haemonetics has filed multiple infringement suits against Fresenius Kabi USA, LLC, targeting its Aurora Xi Plasmapheresis System. Another notable case is a suit against Terumo BCT, Inc., alleging infringement by its Rika Plasma Donation System. These cases appear to center on Haemonetics' patented technology for calculating and optimizing the volume of pure plasma collected from donors. In response to litigation, Terumo BCT has also challenged the validity of a Haemonetics patent before the PTAB.